# Generative AI in insurance claims: short briefing

**Audience:** claims, risk, compliance and technology leaders  
**Evidence checked:** February 2026

## Executive view

The realistic near-term role for generative AI (GenAI) is a **claims-handler copilot**: it can find, extract, organise and draft information, while an accountable claims professional remains responsible for consequential decisions. Start with bounded, reversible workflows. Do not treat a fluent answer, fraud score or generated letter as evidence by itself.

## Practical uses and likely benefits

| Claims activity | Sensible GenAI use | Benefit to test |
|---|---|---|
| First notice of loss (FNOL) | Transcribe and summarise calls, extract fields, identify missing information, translate and draft status requests | Less re-keying and faster first response |
| File understanding | Build a chronology; summarise correspondence, invoices, repair estimates and medical records; retrieve applicable policy passages | Less search time and more complete preparation |
| Adjuster support | Retrieve procedures, suggest next questions, draft routine correspondence and explain the evidence in a file | More consistent preparation and communication |
| Triage and routing | Recommend complexity, urgency, specialist assignment or escalation | Earlier attention to severe or unusual claims |
| Fraud and recovery support | Surface inconsistencies, relationships and possible subrogation opportunities for investigation | More productive investigative leads—not findings of fraud |
| Customer service | Draft plain-language updates and evidence requests, with authentication and human escalation | Better access and fewer avoidable handoffs |

These are usually **hybrid systems**: OCR, speech recognition, rules, computer vision and workflow automation may do much of the work. Attribute results to the whole process, not automatically to GenAI.

### What current evidence says

- **EIOPA’s February 2026 survey** of 347 insurers in 25 EU/EEA countries reported that 32% were already using GenAI in claims management, 9% planned to do so within three years and 59% had no current plans. This indicates adoption, not proven customer benefit.
- **Swiss Re reported in June 2025** that its ClaimsGenAI platform, deployed in mid-2024, generated more than 1,000 potential-irregularity alerts and hundreds of third-party recovery opportunities in its first year. These are company-reported activity metrics, not independently audited fraud confirmations, realised savings or evidence of improved fairness.
- The **NAIC Model Bulletin** recognises AI use in claim management, administration/payment and fraud detection, while making clear that existing unfair-claims, consumer-protection and discrimination obligations still apply. It is model guidance, not automatically binding law in every U.S. state.

The strongest value hypothesis is reduced reading, search and drafting time. Evidence is much weaker for GenAI alone improving settlement accuracy, reducing indemnity leakage or producing fairer outcomes. Measure benefits against a comparable non-AI process rather than relying on vendor or insurer case studies.

## Failure modes

1. **Confabulation or omission:** invented policy terms, dates, limits, medical conclusions or repair costs; omitted exclusions; incorrect citations; or the wrong policy version.
2. **Automation bias:** handlers accept a persuasive summary or recommendation without checking the source file. A nominal human click is not meaningful review.
3. **Unfair or inconsistent treatment:** historical labels and proxy variables can skew triage, investigation intensity, service quality or settlement recommendations by geography, language, disability or other characteristics.
4. **Bad fraud signals:** a false positive can delay or stigmatise a legitimate claimant. Generated suspicion is not corroborating evidence.
5. **Medical-data and privacy harm:** claims files may contain health, financial, identity and location data. Leakage can occur through prompts, logs, vendors, access-control errors or cross-claim disclosure.
6. **Security and adversarial evidence:** uploaded documents may contain prompt injection; altered invoices, medical records or deepfake images can mislead models and investigators.
7. **Operational drift:** model, prompt, retrieval-corpus or vendor changes can silently alter results; outages can interrupt claims handling and create an unreviewed backlog.

## Minimum control set

- **Risk-tier the use case.** Begin with internal search, extraction, summarisation and drafting. Require stronger approval for triage, fraud, medical or payment recommendations. As a default, prohibit autonomous denials, closures, payment reductions, coverage determinations and fraud findings unless a separately justified, validated and lawful use case is approved.
- **Ground outputs in authoritative sources.** Use access-controlled retrieval from the applicable policy, endorsements, claim file and jurisdictional procedures. Show document identifiers and source spans (page references where available), validate effective dates, and abstain when evidence is missing or contradictory.
- **Retain substantive human authority.** The reviewer must see underlying evidence, have time and authority to reject the output, record an independent rationale and escalate high-severity, vulnerable, exceptional or low-evidence cases. For medical claims, use a defined purpose and legal basis, restrict health-data access and require qualified review before an AI inference affects coverage, causation, necessity, reserves or payment.
- **Treat fraud output only as a lead.** Never deny, delay, intensify investigation or impose adverse treatment solely because of a model score or generated suspicion; require corroboration and document the basis for action.
- **Protect claimant interactions.** Authenticate before disclosing claim, medical, payment or policy information. Use controlled, verified templates and authorised review for denials, reservation-of-rights, settlement, limitation and deadline communications. Preserve complaint, appeal, correction and non-digital access routes.
- **Validate and monitor outcomes.** Before launch and after material changes, test factual accuracy, omissions, similar-claim consistency, poor scans, languages, accessibility, rare/catastrophe cases, prompt injection and manipulated evidence. Monitor by product, jurisdiction, language, severity and vulnerability: errors, overrides, complaints, appeals, reopenings, payment/denial/delay/referral rates and disparate outcomes.
- **Preserve evidence and resilience.** Log inputs, retrieved sources, model/prompt/workflow versions, output, human edits, rationale, overrides and timestamps under a documented retention schedule. Contract for confidentiality, no unauthorised training, audit rights, incident and model-change notification, rollback and exit. Maintain manual processing and a plan to identify and remediate claims affected during a defective model period.

## A sensible 90-day pilot

1. Inventory and risk-tier current experiments; name an accountable claims executive.
2. Pilot one bounded internal workflow—such as policy retrieval or file summarisation—in shadow mode, with no write-back to coverage, fraud, medical or payment decisions.
3. Use a holdout set containing complex, multilingual, vulnerable and poor-quality files. Set go/no-go thresholds in advance for accuracy, omissions, subgroup outcomes, overrides and complaints.
4. Expand only when measured claimant and claims outcomes improve without unacceptable new risk.

**Regulatory caveat:** requirements vary by jurisdiction and use. Assess applicable insurance, unfair-claims, prompt-payment, privacy, discrimination and recordkeeping rules. Where automated processing materially affects a person, assess applicable automated-decision, transparency, human-intervention, special-category-data and impact-assessment requirements; GDPR Article 22 may be relevant. In the EU, AI Act classification depends on the system’s actual function—claims involvement alone does not determine whether it is high-risk.

## Sources

- [EIOPA, *Generative AI Market Survey* (2 February 2026)](https://www.eiopa.europa.eu/publications/generative-ai-market-survey-outlook-use-cases-and-risk-management_en)
- [Swiss Re, ClaimsGenAI case study (20 June 2025)](https://www.swissre.com/risk-knowledge/advancing-societal-benefits-digitalisation/how-generative-ai-is-transforming-insurance-claims-claimsgenai.html)
- [NAIC, *Model Bulletin: Use of Artificial Intelligence Systems by Insurers* (4 December 2023)](https://content.naic.org/sites/default/files/inline-files/2023-12-4%20Model%20Bulletin_Adopted_0.pdf)
- [EIOPA, Opinion on AI governance and risk management (6 August 2025)](https://www.eiopa.europa.eu/eiopa-publishes-opinion-ai-governance-and-risk-management-2025-08-06_en)
- [NIST, *AI RMF Generative AI Profile* (2024)](https://www.nist.gov/publications/artificial-intelligence-risk-management-framework-generative-artificial-intelligence)
- [IAIS, application paper on supervision of AI (2025)](https://www.iais.org/2025/07/the-iais-publishes-application-paper-on-the-supervision-of-artificial-intelligence/)
